tetano
Editor, Senior Moderator
Pediatr Blood Cancer
. 2023 May 17;e30402.
doi: 10.1002/pbc.30402. Online ahead of print. Outcomes of SARS-CoV-2 infection in 126 children and adolescents with central nervous system tumors
Daniel C Moreira[SUP] 1 [/SUP], Ibrahim Qaddoumi[SUP] 1 [/SUP], Yichen Chen[SUP] 1 [/SUP], Nickhill Bhakta[SUP] 1 [/SUP], Guillermo L Chantada[SUP] 2 3 [/SUP], Victor M Santana[SUP] 1 [/SUP], Miguela A Caniza[SUP] 1 [/SUP], Meenakshi Devidas[SUP] 1 [/SUP], Kathy Pritchard-Jones[SUP] 4 [/SUP], Carlos Rodriguez-Galindo[SUP] 1 [/SUP], Eric Bouffet[SUP] 5 [/SUP], Sheena Mukkada[SUP] 1 [/SUP]; Global Registry of COVID-19 in Childhood Cancer[SUP] 1 [/SUP]
Affiliations
Background: The Global Registry of COVID-19 in Childhood Cancer (GRCCC) seeks to describe the natural history of SARS-CoV-2 in children with cancer across the world. Here, we report the disease course and management of coronavirus disease 2019 (COVID-19) infection in the subset of children and adolescents with central nervous system (CNS) tumors who were included in the GRCCC until February 2021, the first data freeze.
Procedure: The GRCCC is a deidentified web-based registry of patients less than 19 years of age with cancer or recipients of a hematopoietic stem cell transplant and laboratory-confirmed SARS-CoV-2 infection. Demographic data, cancer diagnosis, cancer-directed therapy, and clinical characteristics of SARS-CoV-2 infection were collected. Outcomes were collected at 30 and 60 days post infection.
Results: The GRCCC included 1500 cases from 45 countries, including 126 children with CNS tumors (8.4%). Sixty percent of the cases were from middle-income countries, while no cases were reported from low-income countries. Low-grade gliomas, high-grade gliomas, and CNS embryonal tumors were the most common CNS cancer diagnoses (67%, 84/126). Follow-up at 30 days was available for 107 (85%) patients. Based on the composite measure of severity, 53.3% (57/107) of reported SARS-CoV-2 infections were asymptomatic, 39.3% (42/107) were mild/moderate, and 6.5% (7/107) were severe or critical. One patient died from SARS-CoV-2 infection. There was a significant association between infection severity and absolute neutrophil count less than 500 (p = .04). Of 107 patients with follow-up available, 40 patients (37.4%) were not receiving cancer-directed therapy. Thirty-four patients (50.7%) had a modification to their treatment due to withholding of chemotherapy or delays in radiotherapy or surgery.
Conclusion: In this cohort of patients with CNS tumors and COVID-19, the frequency of severe infection appears to be low, although severe disease and death do occur. We found that greater severity was seen in patients with severe neutropenia, although treatment modifications were not associated with infection severity or cytopenias. Additional analyses are needed to further describe this unique group of patients.
. 2023 May 17;e30402.
doi: 10.1002/pbc.30402. Online ahead of print. Outcomes of SARS-CoV-2 infection in 126 children and adolescents with central nervous system tumors
Daniel C Moreira[SUP] 1 [/SUP], Ibrahim Qaddoumi[SUP] 1 [/SUP], Yichen Chen[SUP] 1 [/SUP], Nickhill Bhakta[SUP] 1 [/SUP], Guillermo L Chantada[SUP] 2 3 [/SUP], Victor M Santana[SUP] 1 [/SUP], Miguela A Caniza[SUP] 1 [/SUP], Meenakshi Devidas[SUP] 1 [/SUP], Kathy Pritchard-Jones[SUP] 4 [/SUP], Carlos Rodriguez-Galindo[SUP] 1 [/SUP], Eric Bouffet[SUP] 5 [/SUP], Sheena Mukkada[SUP] 1 [/SUP]; Global Registry of COVID-19 in Childhood Cancer[SUP] 1 [/SUP]
Affiliations
- PMID: 37194498
- DOI: 10.1002/pbc.30402
Background: The Global Registry of COVID-19 in Childhood Cancer (GRCCC) seeks to describe the natural history of SARS-CoV-2 in children with cancer across the world. Here, we report the disease course and management of coronavirus disease 2019 (COVID-19) infection in the subset of children and adolescents with central nervous system (CNS) tumors who were included in the GRCCC until February 2021, the first data freeze.
Procedure: The GRCCC is a deidentified web-based registry of patients less than 19 years of age with cancer or recipients of a hematopoietic stem cell transplant and laboratory-confirmed SARS-CoV-2 infection. Demographic data, cancer diagnosis, cancer-directed therapy, and clinical characteristics of SARS-CoV-2 infection were collected. Outcomes were collected at 30 and 60 days post infection.
Results: The GRCCC included 1500 cases from 45 countries, including 126 children with CNS tumors (8.4%). Sixty percent of the cases were from middle-income countries, while no cases were reported from low-income countries. Low-grade gliomas, high-grade gliomas, and CNS embryonal tumors were the most common CNS cancer diagnoses (67%, 84/126). Follow-up at 30 days was available for 107 (85%) patients. Based on the composite measure of severity, 53.3% (57/107) of reported SARS-CoV-2 infections were asymptomatic, 39.3% (42/107) were mild/moderate, and 6.5% (7/107) were severe or critical. One patient died from SARS-CoV-2 infection. There was a significant association between infection severity and absolute neutrophil count less than 500 (p = .04). Of 107 patients with follow-up available, 40 patients (37.4%) were not receiving cancer-directed therapy. Thirty-four patients (50.7%) had a modification to their treatment due to withholding of chemotherapy or delays in radiotherapy or surgery.
Conclusion: In this cohort of patients with CNS tumors and COVID-19, the frequency of severe infection appears to be low, although severe disease and death do occur. We found that greater severity was seen in patients with severe neutropenia, although treatment modifications were not associated with infection severity or cytopenias. Additional analyses are needed to further describe this unique group of patients.